Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2012

View Archived Issues

Evotec and Probiodrug enter development collaboration for novel enzyme target

Kythera's ATX-101 is safe in interim study results

Proof-of-concept results reported for BAY-94-8862

Starpharma reports data from two phase III VivaGel studies

PAX2 identified in CNS hemangioblastomas

Shionogi & Co. presents new NPY5 receptor antagonists

RVX-297 reduces clinical signs of disease in a rat model of rheumatoid arthritis

First-in-human study of AT-406 described

Novel PDE10 inhibitors disclosed by Mochida Pharmaceutical

Exelixis prepares new iPFK2 inhibitors for cancer

Curis licenses GDC-0917 from Genentech

Shionogi & Co. presents new BACE1 inhibitors

Merck & Co. updates on ridaforolimus MAA

Japan Tobacco designs novel RORgamma antagonists

Protalex treats first patient phase Ib PRTX-100 trial

MM-938 significantly reduces tumor growth rates in glioblastoma mouse models

Novel protein kinase inhibitors patented by Abbott Laboratories

Nordic Pharma gains marketing rights for Veregen in certain countries

Preclinical and phase I data presented for AP-26113

Bayer and Leiden University to coordinate drug discovery consortium

Tekmira acquires license to RNAi technology

Phase II trial of pancreas cancer vaccines completes enrollment

Immunovative Therapies receives clearance for phase II/III trial in Thailand

Novel mouse model of NSF developed at Thomas Jefferson University

FDA approves Cometriq, EMA accepts MAA

Enrollment complete in pivotal U.S. phase III trial of NX-1207

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...